Emmaus Life Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

SUBSEQUENT EVENTS (Details Narrative)

SUBSEQUENT EVENTS (Details Narrative) ₩ in Millions			1 Months Ended		3 Months Ended
SUBSEQUENT EVENTS (Details Narrative) ₩ in Millions	Apr. 01, 2023 USD ($) shares	Jul. 12, 2017 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 KRW (₩)	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Apr. 24, 2023 USD ($)	Apr. 24, 2023 KRW (₩)	Jan. 31, 2023 USD ($)
Subsequent Event [Line Items]
Revenue, net					$ 6,753,000	$ 3,234,000
Convertible Promissory Note [Member]
Subsequent Event [Line Items]
Principal amount									$ 1,000,000
Telcon RF Pharmaceuticals, Inc. ("Telcon") [Member] \| Revised API Agreement [Member]
Subsequent Event [Line Items]
Annual purchase target amount		$ 5,000,000
Target profit		$ 2,500,000
Telcon RF Pharmaceuticals, Inc. ("Telcon") [Member] \| API Supply Agreement [Member]
Subsequent Event [Line Items]
Cash proceeds to shortfall in revenue and profits			$ 236,000	₩ 307
Telcon RF Pharmaceuticals, Inc. ("Telcon") [Member] \| API Supply Agreement [Member] \| Minimum [Member]
Subsequent Event [Line Items]
Annual revenue					5,000,000
Telcon RF Pharmaceuticals, Inc. ("Telcon") [Member] \| API Supply Agreement [Member] \| Maximum [Member]
Subsequent Event [Line Items]
Revenue, net					$ 2,500,000
Subsequent Event [Member] \| Convertible Promissory Note [Member]
Subsequent Event [Line Items]
Principal amount	$ 1,000,000
Shares converted into common stock \| shares	2,702,702
Subsequent Event [Member] \| Telcon RF Pharmaceuticals, Inc. ("Telcon") [Member] \| API Supply Agreement [Member]
Subsequent Event [Line Items]
Offset amount against principal amount of convertible bond							$ 2,200,000	₩ 2,900